Rankings
▼
Calendar
BCRX (BioCryst Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena
BCRX
BioCryst Pharmaceuticals, Inc.
Mkt Cap
$2B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$875M
Net Income (TTM)
$264M
EPS (TTM)
$1.20
Free Cash Flow (TTM)
$328M
Gross Margin
97.7%
Op. Margin
39.0%
Net Margin
30.2%
FCF Margin
37.5%
P/S Ratio (TTM)
2.1x
P/E Ratio (TTM)
7.0x
YoY Rev Growth
+94.1%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$69M
$68M
-$28M
Q2 23
$82M
$82M
-$21M
Q3 23
$87M
$86M
-$12M
Q4 23
$93M
$92M
-$43M
Q1 24
$93M
$91M
-$14M
Q2 24
$109M
$108M
$9M
Q3 24
$117M
$114M
$8M
Q4 24
$132M
$125M
-$5M
Q1 25
$146M
$141M
$21M
Q2 25
$163M
$161M
$30M
Q3 25
$159M
$157M
$30M
Q4 25
$407M
$397M
$260M
marketcaparena.com
Revenue Breakdown
BCRX
BioCryst Pharmaceuticals, Inc.
Revenue Breakdown
Q4 2025
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
6.4x
—
Q2 23
6.0x
—
Q3 23
5.8x
—
Q4 23
5.6x
—
Q1 24
5.2x
—
Q2 24
4.8x
—
Q3 24
4.5x
—
Q4 24
4.1x
—
Q1 25
3.7x
—
Q2 25
3.3x
—
Q3 25
3.1x
—
Q4 25
2.1x
7.0x
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$48M
-$48M
Q2 23
-$19M
-$19M
Q3 23
-$20M
-$21M
Q4 23
-$9M
-$9M
Q1 24
-$54M
-$54M
Q2 24
-$1M
-$2M
Q3 24
$8M
$8M
Q4 24
-$5M
-$6M
Q1 25
-$28M
-$28M
Q2 25
$41M
$41M
Q3 25
$41M
$40M
Q4 25
$276M
$275M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$160K
Q2 23
$467K
Q3 23
$987K
Q4 23
$554K
Q1 24
$235K
Q2 24
$155K
Q3 24
$59K
Q4 24
$675K
Q1 25
$143K
Q2 25
$179K
Q3 25
$1M
Q4 25
$802K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
+37.8%
-2.7%
Q2 23
+25.9%
+2.9%
Q3 23
+14.4%
+5.8%
Q4 23
+17.4%
+8.1%
Q1 24
+34.9%
+10.3%
Q2 24
+32.5%
-2.5%
Q3 24
+35.0%
+10.9%
Q4 24
+40.8%
-0.0%
Q1 25
+56.9%
+15.9%
Q2 25
+49.4%
+32.8%
Q3 25
+36.1%
+18.7%
Q4 25
+209.1%
+7.4%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$14M
20.4%
Q2 23
$13M
15.6%
Q3 23
$12M
14.2%
Q4 23
$16M
17.7%
Q1 24
$14M
14.7%
Q2 24
$13M
12.0%
Q3 24
$17M
14.7%
Q4 24
$21M
16.2%
Q1 25
$21M
14.7%
Q2 25
$21M
13.0%
Q3 25
$0
0.0%
Q4 25
$73M
17.8%
marketcaparena.com
OpEx Breakdown
R&D
SG&A
Quarter
R&D
SG&A
Q1 23
$48M
$48M
Q2 23
$51M
$51M
Q3 23
$47M
$51M
Q4 23
$70M
$64M
Q1 24
$46M
$59M
Q2 24
$38M
$61M
Q3 24
$41M
$65M
Q4 24
$49M
$80M
Q1 25
$37M
$82M
Q2 25
$43M
$87M
Q3 25
$44M
$83M
Q4 25
$41M
$96M
marketcaparena.com
Revenue Segments
Collaborative and Other Research and Development
Product
Quarter
Collaborative and Other Research and Development
Product
Q3 23
$1M
$85M
Q1 24
$3M
$89M
Q2 24
$1M
$108M
Q3 24
$1M
$116M
Q1 25
$2M
$144M
Q2 25
$923K
$162M
Q3 25
$2M
$158M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$155M
$243M
$398M
Q2 23
$146M
$264M
$411M
Q3 23
$151M
$247M
$398M
Q4 23
$111M
$278M
$389M
Q1 24
$84M
$252M
$337M
Q2 24
$78M
$194M
$272M
Q3 24
$98M
$233M
$331M
Q4 24
$105M
$216M
$321M
Q1 25
$105M
$190M
$295M
Q2 25
$88M
$172M
$260M
Q3 25
$84M
$129M
$213M
Q4 25
$90M
$185M
$275M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
189M
+0.8%
Q2 23
189M
+0.3%
Q3 23
190M
+0.3%
Q4 23
201M
+6.2%
Q1 24
206M
+2.3%
Q2 24
206M
+0.2%
Q3 24
207M
+0.2%
Q4 24
207M
+0.2%
Q1 25
215M
+3.8%
Q2 25
220M
+2.1%
Q3 25
220M
-0.0%
Q4 25
219M
-0.3%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
$272K
50
FY 15
$689K
70
FY 16
$405K
65
FY 17
$296K
85
FY 18
$207K
100
FY 19
$349K
140
FY 20
$72K
246
FY 21
$439K
358
FY 22
$510K
531
FY 23
$618K
536
FY 24
$777K
580
FY 25
$13K
67K
marketcaparena.com